ACEI/ARB+ finerenone
Phase 3Small molecule
ACEI/ARB+ finerenone is one of 21 small molecule programs targeting Membranous Nephropathy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Membranous Nephropathy
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rituxan
RochePhase 3
Xarelto
WWim Janssens
Approved
Coumadin
AAbbott
Approved
Gazyva
RochePhase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
Rayos
RRoxane Laboratories
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
MIL62
BBeijing Mabworks Biotech Co., Ltd.
Phase 3
B007
SShanghai Jiaolian Drug Research and Development Co., Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Membranous Nephropathy1 trial
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT06573411·88 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ACEI/ARB+ finerenone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details